Results 171 to 180 of about 80,065 (270)

The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

International Journal of Cancer, Volume 159, Issue 7, Page 1633-1641, 1 October 2026.
ABSTRACT The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
Martin Griesshammer, Haifa Kathrin Al‐Ali, Gabriela M. Baerlocher, Konstanze Döhner, Steffen Koschmieder, Nicolaus Kröger, Petro E. Petrides, Dominik Wolf, Florian H. Heidel   +8 more
wiley   +1 more source

Telomerase expression and activity in the immortal cnidarian Hydra. [PDF]

Front Cell Dev Biol
Skvortsov DA, Rubtsova MP, Dolzhnikov VS, Zaraisky AG, Eroshkin FM.   +4 more
europepmc   +1 more source

The Role of EVs in the Aging Hematopoietic System

Aging Cell, Volume 25, Issue 10, October 2026.
Extracellular vesicles from aged bone marrow carry pro‐inflammatory cargo that drives blood stem cell decline, while youthful vesicles restore or maintain stem cell function. Circulating vesicles therefore represent both a readout of hematopoietic aging and a potential therapeutic route.
Esra G. Kosebent, Nathalie Havranek, Karoline Kollmann, Kristina Kirschner, Eszter Doma, Kavya Gupta   +5 more
wiley   +1 more source

MYDGF as a telomerase activator and therapeutic target for osteoarthritis. [PDF]

Adv Biotechnol (Singap)
He Y, Li C, Chen K, Wang X, Xu S, Zhou Z, Yin L, Zheng J, Wu Y, Ma W, Songyang Z, Huang Y.   +11 more
europepmc   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, Volume 209, Issue 4, Page 1450-1468, October 2026.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

RTEL1 mutation modifies dyskeratosis congenita caused by a telomerase RNA template mutation. [PDF]

Nat Commun
Deimler N, Orioli A, Holthöfer L, Linke M, Bobon N, Engelhardt V, Erichsen L, Paul NW, Meyer R, Beier F, Schweiger S, Baumann P.   +11 more
europepmc   +1 more source

Splicing Factor Mutations in Clonal Hematopoiesis and Progression to Myeloid Neoplasms

Cancer Science, Volume 117, Issue 10, Page 2609-2618, October 2026.
Splicing factor (SF)‐mutant CH is characterized by relatively late emergence and accelerated clonal expansion in older individuals. This review summarizes its clonal dynamics, disease‐associated consequences of SF mutations in myeloid neoplasms, and candidate mechanisms that may contribute to age‐dependent selection.
Yang Lyu, Yutong Zhang, Ayana Kon
wiley   +1 more source

Author Correction: Renal fibroblasts are involved in fibrogenic changes in kidney fibrosis associated with dysfunctional telomeres

Experimental and Molecular Medicine
Sarita Saraswati, Paula Martínez, Rosa Serrano, Diego Mejías, Osvaldo Graña-Castro, Ruth Álvarez Díaz, Maria A. Blasco   +6 more
doaj   +1 more source

Disease mutations in the N-terminal extension and α2'-helix of dyskerin do not abolish dimerization but disrupt binding to the telomerase RNA. [PDF]

RNA
Qin J, Lambert-Lanteigne P, Garus A, Autexier C.   +3 more
europepmc   +1 more source

Telomeres and Telomerase

The Keio Journal of Medicine, 2000
openaire   +3 more sources